Abstract
This clinical trial summary provides the background and rationale for a randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when administered after tumor resection, in patients with MAGE-A3-positive stages IB, II, and IIIA non-small-cell lung cancer. The study will also evaluate potential side effects of MAGE-A3 ASCIs. The primary endpoint is disease-free survival. The secondary endpoint is prospective validation of the gene signature predictive of benefit from MAGE-A3 ASCI therapy.
MeSH terms
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology*
-
Antigens, Neoplasm / metabolism
-
Biomarkers
-
Cancer Vaccines
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Clinical Trials, Phase III as Topic
-
Disease-Free Survival
-
Gene Expression Profiling
-
Humans
-
Immunotherapy, Active* / adverse effects
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / immunology
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / immunology*
-
Neoplasm Proteins / metabolism
-
Neoplasm Staging
-
Prognosis
-
Randomized Controlled Trials as Topic
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology*
-
Recombinant Proteins / metabolism
-
Secondary Prevention
-
Treatment Outcome
Substances
-
Antigens, Neoplasm
-
Biomarkers
-
Cancer Vaccines
-
MAGEA3 protein, human
-
Neoplasm Proteins
-
Recombinant Proteins